A plan to make drugs in orbit is going commercial

From Lab to Orbit: How Space-Based Drug Manufacturing Is Entering the Commercial Frontier

Imagine a future where life-saving medications aren’t just designed on Earth—but grown in the silent, weightless expanse of space. It sounds like science fiction, but a bold new venture is turning that vision into reality. Varda Space Industries, a California-based startup, has just inked a landmark deal with United Therapeutics, a biotech giant known for its pioneering work in pulmonary disease treatments. Together, they’re launching a new era: commercial drug manufacturing in orbit.

This isn’t just another experiment aboard the International Space Station (ISS). This is a repeatable, scalable process designed to produce pharmaceuticals in microgravity—conditions that could unlock entirely new molecular structures with enhanced therapeutic potential. For the first time, pharmaceuticals made in space are being positioned not as scientific curiosities, but as viable commercial products.

Varda’s approach centers on a simple yet profound principle: gravity distorts chemistry. On Earth, gravity causes convection, sedimentation, and density-driven mixing—forces that influence how molecules arrange themselves during crystallization. In microgravity, these forces vanish, allowing molecules to form more uniform, defect-free crystals. For drugs, this could mean improved bioavailability, longer shelf life, or even entirely new mechanisms of action.

The partnership with United Therapeutics marks a turning point. While space-based experiments have historically been government-funded and small-scale, Varda is offering pharmaceutical companies a repeatable, cost-effective pathway to produce novel drug formulations. Their spacecraft—essentially automated, self-contained labs—will carry drug solutions into low Earth orbit, where they’ll undergo controlled crystallization. Once complete, the solid crystals are returned to Earth via a heat-shielded reentry capsule.

This isn’t just about novelty. It’s about extending the lifecycle of blockbuster drugs. Pharmaceutical companies routinely reformulate existing medications—switching from pills to inhalers, for instance—to maintain patent protection and stay ahead of generic competitors. Varda’s orbital platform offers a radical new tool in that arsenal: the ability to create gravity-defying versions of drugs that may outperform their Earth-bound counterparts.

United Therapeutics, led by visionary CEO Martine Rothblatt, is no stranger to innovation. Rothblatt, who once worked on satellite communications, has transformed the company into a leader in treating pulmonary arterial hypertension—a condition her daughter suffers from. She’s also pushing the boundaries of xenotransplantation, using gene-edited pigs to grow human-compatible organs. Now, she sees space as the next frontier for drug innovation.

“If we can identify even more amazing versions of our drugs in orbit,” Rothblatt says, “that could be transformative.” Her company’s drugs, such as treprostinil, are already complex and challenging to formulate. By sending these compounds into space, United hopes to discover crystalline forms that are more stable, more potent, or easier to administer.

Varda’s business model is strikingly similar to that of companies like Halozyme and MannKind, which profit by helping other drugmakers reformulate their products. But instead of using nanoparticles or specialized delivery devices, Varda uses microgravity as its core technology. The company plans to offer its orbital manufacturing services on a contract basis, charging pharmaceutical firms for each batch produced in space.

The spacecraft Varda uses are compact but sophisticated. Roughly the size of a large refrigerator, each unit contains a crystallization chamber, temperature controls, and sensors to monitor the drug formation process. Once the crystals are ready, the spacecraft deploys a return capsule equipped with a heat shield and parachute system. The capsule reenters Earth’s atmosphere and lands in a designated recovery zone, where the payload is collected and analyzed.

This closed-loop system is designed for repeatability and scalability. Varda aims to launch multiple missions per year, gradually building a portfolio of space-manufactured compounds. Their long-term vision includes establishing a network of orbital pharmaceutical factories, potentially even on dedicated space stations.

But challenges remain. The cost of launching payloads into space is still high—though it has dropped dramatically with reusable rockets like SpaceX’s Falcon 9. Regulatory hurdles also loom large. The FDA has never approved a drug manufactured entirely in space, and establishing quality control standards for orbital production will require new frameworks.

Still, the potential rewards are immense. In microgravity, scientists have observed that protein crystals grow larger and more uniform, enabling better structural analysis. This could accelerate drug discovery by allowing researchers to see molecular details that are obscured on Earth. For example, the structure of a key enzyme involved in HIV was first fully mapped using crystals grown on the ISS.

Beyond pharmaceuticals, space-based manufacturing could revolutionize other industries. Fiber optics, semiconductors, and advanced alloys have all shown promise in microgravity environments. But drugs may be the first to achieve commercial viability, thanks to their high value-to-mass ratio. A few grams of a novel biologic drug can be worth millions.

Varda’s success could also inspire a new wave of “space biotech” startups. Already, companies like Space Forge and Made In Space are exploring manufacturing in orbit. But Varda is unique in its focus on pharmaceuticals as a near-term revenue driver.

The Science Behind Space-Grown Drugs

At the heart of Varda’s innovation is the science of crystallization in microgravity. On Earth, gravity causes denser molecules to sink and lighter ones to rise, creating uneven crystal growth. Convection currents further disrupt the process, leading to imperfections and defects. In space, without these forces, molecules can arrange themselves in near-perfect lattices.

This has profound implications for drug development. Many drugs are administered as crystalline solids, and their effectiveness depends on the arrangement of atoms. A more uniform crystal structure can mean faster dissolution, better absorption, and reduced side effects. For biologics—large, complex molecules like antibodies—this could be a game-changer.

Consider insulin. On Earth, insulin crystals are prone to aggregation, which can reduce potency and cause immune reactions. In microgravity, researchers have grown insulin crystals that are larger and more uniform, potentially leading to safer, more effective formulations.

Another example is monoclonal antibodies, used to treat cancer and autoimmune diseases. These molecules are notoriously difficult to crystallize on Earth. In space, their crystals have been grown with fewer defects, allowing scientists to study their structure in greater detail. This could lead to more targeted therapies with fewer off-target effects.

Varda’s process isn’t limited to crystallization. The company is also exploring continuous manufacturing in orbit, where drug solutions are mixed, reacted, and purified in a single, automated system. This could reduce contamination risks and increase production efficiency.

The Business Case for Orbital Pharma

The pharmaceutical industry is built on patent cliffs—the moment when a drug’s patent expires and generic versions flood the market, slashing profits. To delay this, companies invest heavily in life-cycle management, creating new formulations, delivery methods, or combinations.

Space-based manufacturing offers a radical new strategy. By producing a novel crystalline form of an existing drug, a company could file for a new patent, effectively resetting the clock. This “patent evergreening” tactic is already used with traditional reformulations, but space-grown versions could offer superior clinical benefits, making them harder to challenge.

United Therapeutics stands to gain significantly. Its lead drug, treprostinil, is already available in multiple forms—injected, inhaled, and oral. A space-grown version with improved stability or bioavailability could command a premium price and extend the franchise’s dominance.

Varda’s model is also attractive to smaller biotechs. Instead of investing billions in R&D, a company could pay Varda to grow its drug in orbit, potentially unlocking a new formulation in months rather than years.

The Road Ahead: Challenges and Opportunities

Despite the promise, space-based drug manufacturing faces significant hurdles. Regulatory approval is the biggest. The FDA will need to verify that drugs made in space meet the same safety and efficacy standards as those produced on Earth. This will require new testing protocols and possibly new legislation.

Cost is another factor. While launch prices have fallen, a single mission still costs millions. Varda must demonstrate that the benefits outweigh the expense. For high-value drugs, this may be feasible, but for generics, it likely won’t.

There’s also the risk of mission failure. A launch explosion or reentry malfunction could destroy months of work. Varda mitigates this with redundant systems and rigorous testing, but space remains an unforgiving environment.

Still, the potential is too great to ignore. As space becomes more accessible, orbital manufacturing could become a standard tool in the pharmaceutical toolkit. Imagine a world where the most advanced drugs are grown in the quiet vacuum of space, free from the distortions of gravity.

In the end, Varda and United Therapeutics aren’t just making drugs in orbit—they’re redefining what’s possible. They’re proving that the next frontier of medicine isn’t just in labs or clinics, but among the stars.

This article was curated from A plan to make drugs in orbit is going commercial via MIT Technology Review